LMF Acquisition Opportunities filed a Form S-4 including a preliminary proxy on its proposed business combination with with SeaStar Medical, which is developing extracorporeal therapies to reduce the consequences of excessive inflammation on vital organs.
Announced last month, the deal has a combined enterprise value of $85 million.
The SPAC, which in abbreviated form is known as LMFAO, raised $90 million in a January 2021 IPO with plans at that time to focus on acquiring a business within the financial services industry and related sectors, including FinTech. The company was focusing on acquisitions with an enterprise value of approximately $250 million to $500 million.
The Dow Chemical Company Pension Plans, as existing investors of SeaStar Medical, are participating in a PIPE supporting the deal. Read more.
